Peak6 Investments LP Increased Nexstar Media Group (Put) (NXST) Holding; Alkermes (ALKS)’s Sentiment Is 1.12

December 7, 2017 - By Dolores Ford

Peak6 Investments Lp increased Nexstar Media Group Inc (Put) (NXST) stake by 57.7% reported in 2017Q2 SEC filing. Peak6 Investments Lp acquired 17,600 shares as Nexstar Media Group Inc (Put) (NXST)’s stock declined 15.04%. The Peak6 Investments Lp holds 48,100 shares with $2.88 million value, up from 30,500 last quarter. Nexstar Media Group Inc (Put) now has $3.26B valuation. The stock increased 0.51% or $0.3615 during the last trading session, reaching $71.5615. About 155,068 shares traded. Nexstar Media Group, Inc. (NASDAQ:NXST) has risen 19.43% since December 7, 2016 and is uptrending. It has outperformed by 2.73% the S&P500.

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products that are designed to address unmet medical needs of patients in various therapeutic areas worldwide. The company has market cap of $8.15 billion. The companyÂ’s marketed products include ARISTADA for the treatment of schizophrenia; VIVITROL (naltrexone for extended-release injectable suspension) for the treatment of alcohol and opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA for treating schizophrenia; AMPYRA (dalfampridine)/FAMPYRA (fampridine) to enhance walking in adults with multiple sclerosis who have walking disability; and BYDUREON (exenatide extended-release for injectable suspension) for the treatment of type 2 diabetes. It currently has negative earnings. It is also developing ALKS 5461 that is in Phase III clinical trials for the treatment of depressive disorder; ALKS 3831, which is in Phase III clinical trials to treat schizophrenia; ALKS 8700, a monomethyl fumarate molecule, which is in Phase III clinical trials to treat multiple sclerosis; ALKS 6428, which is in Phase III clinical trials to help physicians transition patients from physical dependence on opioids; and Aripiprazole lauroxil, an injectable atypical antipsychotic, which has completed a Phase I clinical trials for the treatment of schizophrenia, as well as ALKS 4230, a cell activator that is in Phase I clinical trials for cancer immunotherapy.

Ratings analysis reveals 100% of Alkermes’s analysts are positive. Out of 3 Wall Street analysts rating Alkermes, 3 give it “Buy”, 0 “Sell” rating, while 0 recommend “Hold”. The lowest target is $70.0 while the high is $70.0. The stock’s average target of $70 is 32.10% above today’s ($52.99) share price. ALKS was included in 3 notes of analysts from October 21, 2016. Leerink Swann maintained Alkermes plc (NASDAQ:ALKS) rating on Friday, October 21. Leerink Swann has “Outperform” rating and $70.0 target. JP Morgan upgraded the stock to “Overweight” rating in Friday, October 21 report. The rating was maintained by Jefferies on Friday, October 21 with “Buy”.

Meditor Group Ltd holds 8.99% of its portfolio in Alkermes plc for 1.03 million shares. Opus Point Partners Management Llc owns 42,623 shares or 2.27% of their US portfolio. Moreover, Jag Capital Management Llc has 2.19% invested in the company for 188,682 shares. The New York-based Roanoke Asset Management Corp Ny has invested 2.09% in the stock. Kelly Lawrence W & Associates Inc Ca, a California-based fund reported 118,100 shares.

The stock increased 0.43% or $0.23 during the last trading session, reaching $52.99. About 68,870 shares traded. Alkermes plc (ALKS) has risen 47.50% since December 7, 2016 and is uptrending. It has outperformed by 30.80% the S&P500.

Analysts await Alkermes plc (NASDAQ:ALKS) to report earnings on February, 21. They expect $-0.01 EPS, up 75.00% or $0.03 from last year’s $-0.04 per share. After $-0.09 actual EPS reported by Alkermes plc for the previous quarter, Wall Street now forecasts -88.89% EPS growth.

Investors sentiment decreased to 1.14 in 2017 Q2. Its down 1.43, from 2.57 in 2017Q1. It dived, as 42 investors sold NXST shares while 57 reduced holdings. 37 funds opened positions while 76 raised stakes. 47.98 million shares or 7.89% more from 44.47 million shares in 2017Q1 were reported. Morgan Stanley invested in 0.01% or 329,027 shares. Nomura Holdings holds 0.01% or 38,892 shares. Bluefin Trading Limited Liability Corp reported 6,500 shares. Icon Advisers holds 6,800 shares. Sg Americas Secs Limited Liability Company stated it has 3,418 shares. Putnam Investments Ltd Limited Liability Company invested in 27,474 shares. Blackrock Incorporated owns 0.01% invested in Nexstar Media Group, Inc. (NASDAQ:NXST) for 2.78M shares. Alpine Woods Cap Investors Llc holds 0.01% or 3,935 shares in its portfolio. Barclays Public Limited Company holds 0% or 32,571 shares. S Muoio And Lc holds 1.69% or 59,113 shares. 1.11 million were accumulated by Scopus Asset Mngmt L P. Community Financial Bank Na holds 50 shares. Verition Fund Mngmt Ltd Limited Liability Company owns 5,000 shares. Ftb Advisors Incorporated owns 500 shares for 0% of their portfolio. Millennium Ltd Liability, New York-based fund reported 651,242 shares.

Among 9 analysts covering Nexstar Broadcasting Group (NASDAQ:NXST), 9 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Nexstar Broadcasting Group had 30 analyst reports since August 5, 2015 according to SRatingsIntel. As per Wednesday, March 1, the company rating was maintained by Benchmark. As per Monday, September 18, the company rating was maintained by Jefferies. The stock of Nexstar Media Group, Inc. (NASDAQ:NXST) earned “Buy” rating by Jefferies on Thursday, July 13. The firm has “Outperform” rating given on Monday, November 14 by Barrington Research. The stock of Nexstar Media Group, Inc. (NASDAQ:NXST) has “Buy” rating given on Monday, August 14 by Jefferies. The stock has “Buy” rating by Deutsche Bank on Friday, October 20. RBC Capital Markets maintained Nexstar Media Group, Inc. (NASDAQ:NXST) on Monday, November 6 with “Buy” rating. The stock has “Hold” rating by Zacks on Wednesday, August 5. As per Wednesday, November 8, the company rating was maintained by Deutsche Bank. The rating was maintained by RBC Capital Markets on Wednesday, August 9 with “Buy”.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By1 Dolores Ford




Automatic Stock Updates

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Recent Posts